209 related articles for article (PubMed ID: 33204410)
1. Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
Conti RM; David FS
F1000Res; 2020; 9():707. PubMed ID: 33204410
[TBL] [Abstract][Full Text] [Related]
2. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
3. The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.
Wolitz RE
J Leg Med; 2019; 39(2):177-211. PubMed ID: 31503531
[TBL] [Abstract][Full Text] [Related]
4. Policy Recommendations for Pharmacy Benefit Managers to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
Daniel H; Bornstein SS;
Ann Intern Med; 2019 Dec; 171(11):823-824. PubMed ID: 31711103
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical drug development: high drug prices and the hidden role of public funding.
Annett S
Biol Futur; 2021 Jun; 72(2):129-138. PubMed ID: 34554467
[TBL] [Abstract][Full Text] [Related]
6. Regulating Drug Prices while Increasing Innovation.
Conti RM; Frank RG; Gruber J
N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
[No Abstract] [Full Text] [Related]
7. Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?
Neumann PJ; Cohen JT; Ollendorf DA
N Engl J Med; 2021 Nov; 385(21):1923-1924. PubMed ID: 34767318
[No Abstract] [Full Text] [Related]
8. Price Models for Multi-indication Drugs: A Systematic Review.
Campillo-Artero C; Puig-Junoy J; Segú-Tolsa JL; Trapero-Bertran M
Appl Health Econ Health Policy; 2020 Feb; 18(1):47-56. PubMed ID: 31523756
[TBL] [Abstract][Full Text] [Related]
9. Should the United States government regulate prescription prices? A critical review.
Patterson JA; Carroll NV
Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
[TBL] [Abstract][Full Text] [Related]
10. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
Sarpatwari A; Avorn J; Kesselheim AS
BMJ; 2020 Oct; 371():m3841. PubMed ID: 33032982
[No Abstract] [Full Text] [Related]
11. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
Kaltenboeck A
Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
[TBL] [Abstract][Full Text] [Related]
12. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada.
Gaffney A; Lexchin J; ;
BMJ; 2018 May; 361():k1039. PubMed ID: 29773533
[No Abstract] [Full Text] [Related]
13. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
Jayadev A; Stiglitz J
Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
[TBL] [Abstract][Full Text] [Related]
14. Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach.
Fuller RL; Goldfield N
J Ambul Care Manage; 2016; 39(2):143-9. PubMed ID: 26945298
[TBL] [Abstract][Full Text] [Related]
15. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
Bell H
Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
[TBL] [Abstract][Full Text] [Related]
16. Do market components account for higher US prescription prices?
Monaghan MJ; Monaghan MS
Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
[TBL] [Abstract][Full Text] [Related]
17. The Economics of Indication-Based Drug Pricing.
Chandra A; Garthwaite C
N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
[No Abstract] [Full Text] [Related]
18. Value-Based Pricing and Patient Access for Specialty Drugs.
Robinson JC; Howell S; Pearson SD
JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
[No Abstract] [Full Text] [Related]
19. Funding pharmaceutical innovation through direct tax credits.
Lybecker KM; Freeman RA
Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
[TBL] [Abstract][Full Text] [Related]
20. Prices gone wild: grey market 'scalpers' scoring windfall in American drug market.
Woodward C
CMAJ; 2012 Feb; 184(2):E119-20. PubMed ID: 22231687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
